Developing aptamers into therapeutics

Journal of Clinical Investigation

Volumn 106, Issue 8, 2000, Pages 929-934

  White, Rebekah R ^a   Sullenger, Bruce A ^a   Rusconi, Christopher P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; NUCLEIC ACID; PEGAPTANIB; THROMBIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS RNA;

ANGIOGENESIS; ANTICOAGULATION; ARTERY INTIMA PROLIFERATION; ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; BLOOD CLOTTING; CLINICAL TRIAL; DISSOCIATION CONSTANT; DRUG BINDING; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; NUCLEIC ACID STRUCTURE; PRIORITY JOURNAL; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN TARGETING; RNA SEQUENCE; RNA TRANSCRIPTION; SIDE EFFECT; THROMBOSIS; TRANSCRIPTION REGULATION; VIRUS REPLICATION;

EID: 0033791140     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11325     Document Type: Article

References (34)

1. Diversity of oligonucleotide functions
2. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication
3. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children
4. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase
5. In vitro selection of RNA molecules that bind specific ligands
6. Isozyme-specific inhibition of protein kinase C by RNA aptamers
7. Blocking the initiation of coagulation by RNA aptamers to Factor VIIa
8. Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor
9. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies
10. Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes
11. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance
12. 2'-Fluoro- and 2'-amino-2'-deoxynucleoside 5'-triphosphates as substrates for T7 RNA polymerase
13. Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor
14. Liposome-anchored vascular endothelial growth factor aptamers
15. Detection and plasma pharmacokinerics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys
16. Characterization and development of nuclease-resistant synthetic ribozymes as a new class of therapeutics
17. Catalytic DNA as potential therapeutic agents and sequence-specific molecular tools
18. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides
19. Selection of single-stranded DNA molecules that bind and inhibit human thrombin
20. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagularion in extracorporeal circuits
21. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass
22. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation
23. Therapeutic applications of transcription factor decoy oiigonucleotides
24. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo
25. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial
26. Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function
27. Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication
28. Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in a rat model of arterial restenosis
29. Inhibitory DNA ligands to platelet-derived growth factor B-chain
30. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF
31. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
32. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF 165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain
33. VEGF(165) mediates glomerular endothelial repair
34. Novel approach to specific growth factor inhibition in vivo: Antagonism of platelet-derived growth factor in glomerulonephriris by aptamers